Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14717920 | 0.94 | SCN9A (0.33) | FAAHSCN9A | |
| SCHEMBL14727732 | 0.94 | BRD4 (0.32) | BRD4POLB | |
| SCHEMBL14727775 | 0.93 | BRD4 (0.31) | BRD4SCN9A | |
| SCHEMBL14727776 | 0.92 | BRD4 (0.32) | BRD4SCN9A | |
| SCHEMBL14727778 | 0.89 | TGFBR1 (0.33) | FAAHBRD4 | |
| SCHEMBL6903516 | 0.89 | ACSS2 (0.34) | SCN9A | |
| SCHEMBL14727762 | 0.88 | NR1H2 (0.33) | FAAHBRD4SCN9A | |
| SCHEMBL14718605 | 0.88 | SCN9A (0.33) | FAAHSCN9A | |
| SCHEMBL14718169 | 0.88 | CYP17A1 (0.32) | SCN9A | |
| SCHEMBL14727729 | 0.88 | F2 (0.34) | BRD4SCN9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | BACE1, BACE2, GSAP | FAAH 55/4885BRD4 389/4885SCN9A 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.